Protocol Ledger

NCT06511869 · Phase II · COMPLETED

AZD4205 in Peripheral T Cell Lymphoma Following First-Line Therapy (JACKPOT26)

Interventional Phase II clinical trial protocol NCT06511869 sponsored by Dizal Pharmaceuticals in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-03-17 Enrollment: 48 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06511869
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)48 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06511869
Protocol FieldVerified Registry Value
NCT IdentifierNCT06511869
Consolidated Lead SponsorDizal Pharmaceuticals
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment48 participants (ACTUAL)
Registered Start Date2022-03-17
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI